- Home
- IHT vs KZIA Comparison
IHT vs KZIA Comparison
Compare IHT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHT | KZIA |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | Australia |
| Employees | N/A | 6 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 186.7M |
| IPO Year | 1995 | 2002 |
Fundamental Metrics
Financial Performance| Metric | IHT | KZIA |
|---|---|---|
| Price | $1.34 | $11.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 21.9K | ★ 263.3K |
| Earning Date | 05-12-2026 | 06-04-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $7,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $4.86 |
| 52 Week High | $4.24 | $17.40 |
Technical Indicators
Market Signals| Indicator | IHT | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 38.77 |
| Support Level | $1.23 | $7.25 |
| Resistance Level | $1.51 | $14.85 |
| Average True Range (ATR) | 0.10 | 1.15 |
| MACD | 0.00 | -0.30 |
| Stochastic Oscillator | 37.18 | 5.04 |
Price Performance
Historical ComparisonAbout IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.